Gemtesa® (vibegron) – New indication
December 18, 2024 - The FDA approved Sumitomo Pharma’s Gemtesa (vibegron), for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).